Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Kineret | anakinra | Still's disease | Withdrawn | |||
| Ledaga | chlormethine hydrochloride | T-cell lymphoma | Do not reimburse | Complete | ||
| Saxenda | liraglutide | Chronic weight management in adults | Do not reimburse | Complete | ||
| Rinvoq | upadacitinib | Psoriatic Arthritis, adults | Reimburse with clinical criteria and/or conditions | Complete | ||
| Venclexta | venetoclax | Acute myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vyxeos | daunorubicin and cytarabine | Acute myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Trikafta | elexacaftor / tezacaftor / ivacaftor and ivacaftor | Cystic fibrosis, F508del CFTR mutation | Reimburse with clinical criteria and/or conditions | Complete | ||
| Venclexta | venetoclax | Acute myeloid leukemia | Do not reimburse | Complete | ||
| Entuzity KwikPen | human insulin | Diabetes mellitus | Reimburse with clinical criteria and/or conditions | Complete | ||
| Reblozyl | luspatercept | Myelodysplastic syndromes-associated anemia | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 27, 2024